Elutia Gestion
Gestion contrôle des critères 3/4
Le PDG Elutia est Randy Mills, nommé en Jun2022, a un mandat de 3.92 ans. La rémunération annuelle totale est $ 1.34M, composée du salaire de 44.6% et des bonus 55.4%, y compris les actions et options de la société. détient directement 0.93% des actions de la société, d'une valeur de $ 474.91K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 3.8 ans et 5.7 ans.
Informations clés
Randy Mills
Directeur général
US$1.3m
Rémunération totale
| Pourcentage du salaire du PDG | 44.63% |
| Durée du mandat du directeur général | 3.9yrs |
| Propriété du PDG | 0.9% |
| Durée moyenne d'occupation des postes de direction | 3.8yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 5.7yrs |
Mises à jour récentes de la gestion
Recent updates
Mise à jour du récit • Mar 04
ELUT: Listing Compliance Recovery Will Support Future Reconstructive Portfolio Upside
Analysts have adjusted their price target on Elutia to reflect updated views on profitability, with a lower assumed profit margin and a higher future P/E estimate shaping the new valuation in dollar terms. What's in the News Elutia received a written notice from Nasdaq on December 23, 2025 stating that it is not in compliance with the minimum market value of listed securities requirement of $35 million under Nasdaq Listing Rule 5550(b)(2) (Key Developments).Mise à jour du récit • Feb 18
ELUT: Listing Compliance Progress Will Support Future Reconstructive Portfolio Upside
Analysts have revised their price target on Elutia to $3.50, maintaining their fair value estimate while updating assumptions on the discount rate, revenue growth, profit margin, and future P/E to align with their current assessment of the company’s risk and earnings profile. What's in the News Elutia received a written notice from Nasdaq stating that it is not in compliance with the minimum market value of listed securities requirement of $35m under Listing Rule 5550(b)(2).Article d’analyse • Feb 15
Elutia Inc. (NASDAQ:ELUT) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Elutia Inc. ( NASDAQ:ELUT ) shares have continued their recent momentum with a 28% gain in the last month alone. But...
Mise à jour du récit • Feb 04
ELUT: Future Nasdaq Compliance Resolution Will Support Bullish Repricing Potential
Analysts have maintained their price target on Elutia at US$5.00, citing a slightly lower discount rate, a modest change in expected revenue contraction, and a small adjustment to future P/E assumptions, along with a slightly higher projected profit margin. What's in the News On December 23, 2025, Elutia received a Nasdaq notice that its market value of listed securities had been below the US$35 million minimum for 30 consecutive business days, and that it also did not meet certain shareholder equity and net income standards required for continued listing on The Nasdaq Capital Market (Nasdaq notice).Mise à jour du récit • Jan 21
ELUT: Future Nasdaq Compliance Progress Will Drive Bullish Repricing Potential
Narrative Update on Elutia Analysts have maintained their price target for Elutia at US$5.00, citing slightly lower assumed revenue growth, a modestly higher profit margin outlook, and a small adjustment to the discount rate and future P/E assumptions as key drivers behind the updated view. What's in the News On December 23, 2025, Nasdaq notified Elutia that its market value of listed securities had been below the US$35 million minimum required under Listing Rule 5550(b)(2) for 30 consecutive business days, and that the company also did not meet related shareholder equity or net income standards (Nasdaq notice).Mise à jour du récit • Jan 07
ELUT: Future Compliance Recovery Will Support Bullish Repricing Potential
Analysts have reduced their price target on Elutia by US$1.00. They cite a higher discount rate, a projected revenue decline of 7.18%, and a much higher future P/E estimate, partly offset by slightly stronger expected profit margins.Mise à jour du récit • Dec 16
ELUT: Future Listing Compliance Efforts Will Support Reconstructive Portfolio Expansion
Narrative Update on Elutia Analysts have modestly adjusted their price target on Elutia upward to reflect a slightly more constructive long term earnings and valuation outlook, nudging the fair value estimate higher by approximately $0.00 per share as updated model inputs had only a de minimis impact on the overall target. What's in the News Elutia received a notice from Nasdaq that its Class A common stock has traded below the $1.00 per share minimum bid price for 30 consecutive business days, triggering a formal deficiency notification and potential delisting process (Nasdaq listing notice).Article d’analyse • Dec 06
Lacklustre Performance Is Driving Elutia Inc.'s (NASDAQ:ELUT) 28% Price Drop
To the annoyance of some shareholders, Elutia Inc. ( NASDAQ:ELUT ) shares are down a considerable 28% in the last...Mise à jour du récit • Dec 02
ELUT: Recent Business Sale Will Fund Breast Reconstruction Growth Ahead
Analysts have lowered Elutia's target price from $8.00 to $6.00, citing a smaller-than-expected sale price for the BioEnvelope business. However, they note that the deal removes significant overhangs and provides full funding for Elutia's breast reconstruction segment.Mise à jour du récit • Nov 17
ELUT: Recent Business Sale Will Unlock Breast Reconstruction Focus
Narrative Update on Elutia Elutia's analyst price target has been reduced from $8 to $6 following analysts’ assessment that, although the sale of the BioEnvelope business provides significant funding, the lower-than-expected acquisition price tempers near-term expectations for the company's growth. Analyst Commentary Analysts have weighed in on the implications of Elutia's recent business developments, offering a nuanced perspective on the company's outlook.Mise à jour du récit • Nov 01
ELUT: Breast Reconstruction Funding Will Drive Long-Term Shareholder Value
Elutia's analyst price target has decreased from $8 to $6, as analysts factor in the sale of its BioEnvelope business. While this sale is seen as bittersweet, it helps eliminate notable uncertainties and secures funding for the company's breast reconstruction segment.Mise à jour du récit • Oct 17
Aging Demographics And Chronic Conditions Will Spur Healing Advances
Analysts have reduced their price target for Elutia from $8 to $6 per share, citing both the lower-than-expected sale price of its BioEnvelope business and the improved funding outlook for its core breast reconstruction segment. Analyst Commentary Recent analyst reports provide a nuanced view of Elutia's prospects following the BioEnvelope business sale.Article d’analyse • Oct 13
The Market Doesn't Like What It Sees From Elutia Inc.'s (NASDAQ:ELUT) Revenues Yet As Shares Tumble 30%
To the annoyance of some shareholders, Elutia Inc. ( NASDAQ:ELUT ) shares are down a considerable 30% in the last...Mise à jour du récit • Oct 03
Aging Demographics And Chronic Conditions Will Spur Healing Advances
Analysts have reduced their price target for Elutia, with recent adjustments citing a new range from $8 to $5 per share. This reflects cautious optimism about the firm's strategic divestiture and future growth prospects, despite near-term revenue challenges.Mise à jour du récit • Sep 10
Aging Demographics And Chronic Conditions Will Spur Healing Advances
Elutia's fair value estimate has been revised downward due to sharply reduced revenue growth forecasts and a significantly higher future P/E multiple, resulting in the consensus price target dropping from $6.50 to $5.50. What's in the News Elutia was selected to exhibit its EluPro Antibiotic-Eluting BioEnvelope at the Vizient Innovative Technology Exchange, providing exposure to hospital supply chain and clinical leaders.Article d’analyse • Aug 29
Elutia Inc.'s (NASDAQ:ELUT) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Elutia Inc. ( NASDAQ:ELUT ) shareholders have had their patience rewarded with a 27% share price jump in the last...Article d’analyse • Aug 19
US$6.50: That's What Analysts Think Elutia Inc. (NASDAQ:ELUT) Is Worth After Its Latest Results
NasdaqCM:ELUT 1 Year Share Price vs Fair Value Explore Elutia's Fair Values from the Community and select yours Elutia...Mise à jour du récit • Aug 19
FDA Cleared EluPro Launch And Capacity Expansion Will Unlock Opportunity
Despite a substantial increase in consensus revenue growth forecasts and a sharply lower future P/E, Elutia’s consensus analyst price target has been reduced from $7.50 to $6.50. What's in the News Elutia published a study showing its antibiotic-eluting CIED biologic envelope, EluPro, controls inflammation, supports vascularization, and promotes higher growth factor release, potentially reducing scarring and infection risks in implantable cardiac device patients.Article d’analyse • Jun 18
Revenues Working Against Elutia Inc.'s (NASDAQ:ELUT) Share Price
With a price-to-sales (or "P/S") ratio of 3.1x Elutia Inc. ( NASDAQ:ELUT ) may be sending very bullish signals at the...
Nouveau récit • Apr 06
FDA Cleared EluPro Launch And Capacity Expansion Will Unlock Opportunity
EluPro's FDA clearance and market entry against Medtronic's TYRX could drive significant revenue growth in the antibiotic-eluting envelope space.Article d’analyse • Jan 04
Elutia Inc. (NASDAQ:ELUT) Not Doing Enough For Some Investors As Its Shares Slump 27%
Elutia Inc. ( NASDAQ:ELUT ) shares have had a horrible month, losing 27% after a relatively good period beforehand...Article d’analyse • Nov 20
Elutia Inc. (NASDAQ:ELUT) Held Back By Insufficient Growth Even After Shares Climb 26%
Elutia Inc. ( NASDAQ:ELUT ) shareholders would be excited to see that the share price has had a great month, posting a...Article d’analyse • Jun 28
Elutia Inc.'s (NASDAQ:ELUT) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Elutia Inc. ( NASDAQ:ELUT ) shares have continued their recent momentum with a 28% gain in the last month alone...Article d’analyse • Mar 10
News Flash: 2 Analysts Think Elutia Inc. (NASDAQ:ELUT) Earnings Are Under Threat
One thing we could say about the analysts on Elutia Inc. ( NASDAQ:ELUT ) - they aren't optimistic, having just made a...Article d’analyse • Feb 21
Elutia Inc.'s (NASDAQ:ELUT) Share Price Is Matching Sentiment Around Its Revenues
You may think that with a price-to-sales (or "P/S") ratio of 1.5x Elutia Inc. ( NASDAQ:ELUT ) is definitely a stock...Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$22m |
| Dec 31 2025 | US$1m | US$600k | -US$16m |
| Sep 30 2025 | n/a | n/a | -US$25m |
| Jun 30 2025 | n/a | n/a | -US$22m |
| Mar 31 2025 | n/a | n/a | -US$40m |
| Dec 31 2024 | US$5m | US$600k | -US$45m |
| Sep 30 2024 | n/a | n/a | -US$53m |
| Jun 30 2024 | n/a | n/a | -US$65m |
| Mar 31 2024 | n/a | n/a | -US$49m |
| Dec 31 2023 | US$2m | US$600k | -US$41m |
| Sep 30 2023 | n/a | n/a | -US$32m |
| Jun 30 2023 | n/a | n/a | -US$35m |
| Mar 31 2023 | n/a | n/a | -US$38m |
| Dec 31 2022 | US$2m | US$321k | -US$36m |
| Sep 30 2022 | n/a | n/a | -US$39m |
| Jun 30 2022 | n/a | n/a | -US$37m |
| Mar 31 2022 | n/a | n/a | -US$28m |
| Dec 31 2021 | US$146k | n/a | -US$25m |
| Sep 30 2021 | n/a | n/a | -US$21m |
| Jun 30 2021 | n/a | n/a | -US$23m |
| Mar 31 2021 | n/a | n/a | -US$26m |
| Dec 31 2020 | US$142k | n/a | -US$25m |
Rémunération vs marché: La rémunération totale de Randy ($USD 1.34M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 624.15K ).
Rémunération et revenus: La rémunération de Randy a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Randy Mills (53 yo)
3.9yrs
Titularisation
US$1,344,284
Compensation
Dr. C. Randal Mills, Ph D., also known as Randy, has been Director of Elutia Inc. (formerly known as Aziyo Biologics, Inc.) since November 2015. Dr. Mills served as a Member of Advisory Board at eXpanded e...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Co-Founder | 3.9yrs | US$1.34m | 0.93% $ 474.9k | |
| Chief Financial Officer | 5.7yrs | US$747.03k | 1.07% $ 547.6k | |
| Chief Scientific Officer | 3.8yrs | US$688.70k | 0.25% $ 127.4k | |
| Head of People | less than a year | pas de données | pas de données | |
| VP & Head of Emerging Businesses | 4.3yrs | pas de données | pas de données | |
| Head of Cardiovascular | 1yr | pas de données | pas de données | |
| Chief Commercial Officer | less than a year | pas de données | pas de données | |
| Senior VP of Finance | no data | pas de données | pas de données |
3.8yrs
Durée moyenne de l'emploi
55yo
Âge moyen
Gestion expérimentée: L'équipe de direction de ELUT est considérée comme expérimentée (ancienneté moyenne 3.8 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Co-Founder | 10.5yrs | US$1.34m | 0.93% $ 474.9k | |
| Independent Chairman & Lead Independent Director | 10.5yrs | US$321.50k | 1.17% $ 601.5k | |
| Independent Director | 5.7yrs | US$161.00k | 0.061% $ 31.3k | |
| Independent Director | less than a year | US$196.25k | 0.28% $ 145.0k | |
| Independent Director | 3.6yrs | US$138.50k | 0.070% $ 36.1k |
5.7yrs
Durée moyenne de l'emploi
64yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de ELUT sont considérés comme expérimentés (ancienneté moyenne 5.7 ans).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/26 06:48 |
| Cours de l'action en fin de journée | 2026/05/26 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Elutia Inc. est couverte par 6 analystes. 1 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Brandon Folkes | Cantor Fitzgerald & Co. |
| Ross Osborn | Cantor Fitzgerald & Co. |
| Frank Takkinen | Lake Street Capital Markets, LLC |